Linked Life Data

20154472

Source:http://linkedlifedata.com/resource/pubmed/id/20154472

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-15
pubmed:abstractText
Approximately 35-60% of patients with colorectal cancers will develop liver lesions during their life span. Previously colorectal liver metastases have traditionally been categorized as incurable systemic disease. However, the introduction of new chemotherapeutic regimens(e.g. FOLFOX or FOLFIRI)and recent technical innovations(e. g. staged hepatic resection and percutaneous transhepatic portal embolization)has allowed us to perform hepatic resection with curative intent. Additionally, a neoadjuvant strategy has expanded the criteria for liver resection, and more active molecular therapeutic agents are now available. As a result, a recent advancement has enhanced the overall 5-year survival from 30% to 58% for colorectal liver metastases. Despite these facts, many patients still experience a recurrence after hepatic resection. Modern treatment of colorectal liver metastases requires a multimodal approach to increase the number of patients who may benefit from surgical treatment of colorectal liver metastases.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
194-9
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Diagnosis and treatment of liver metastases].
pubmed:affiliation
Dept. of Hepato-Biliary-Pancreatic Surgery, Tohoku University Graduate School of Medicine.
pubmed:publicationType
Journal Article, English Abstract